Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2014 1
2015 2
2016 4
2018 3
2019 1
2020 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hug dh (37 results)?
Over 50 Years of Fibrinogen Concentrate.
Costa-Filho R, Hochleitner G, Wendt M, Teruya A, Spahn DR. Costa-Filho R, et al. Clin Appl Thromb Hemost. 2016 Mar;22(2):109-14. doi: 10.1177/1076029615601494. Epub 2015 Aug 19. Clin Appl Thromb Hemost. 2016. PMID: 26294722 Free PMC article. Review.
A DUAL MTOR/NAD+ ACTING GEROTHERAPY.
Li J, Kumar S, Miachin K, Bean NL, Halawi O, Lee S, Park J, Pierre TH, Hor JH, Ng SY, Wallace KJ, Rindtorff N, Miller TM, Niehoff ML, Farr SA, Kletzien RF, Colca J, Tanis SP, Chen Y, Griffett K, McCommis KS, Finck BN, Peterson TR. Li J, et al. bioRxiv [Preprint]. 2023 Jan 19:2023.01.16.523975. doi: 10.1101/2023.01.16.523975. bioRxiv. 2023. PMID: 36711589 Free PMC article. Preprint.
The geroscience hypothesis states that a therapy that prevents the underlying aging process should prevent multiple aging related diseases. ...In vivo testing indicated that BIOIO-1001 reduced high fat, high sugar diet-induced metabolic derangements, inflammation, a …
The geroscience hypothesis states that a therapy that prevents the underlying aging process should prevent multiple aging related dis …
Predictors of treatment switching in the Big Multiple Sclerosis Data Network.
Spelman T, Magyari M, Butzkueven H, Van Der Walt A, Vukusic S, Trojano M, Iaffaldano P, Horáková D, Drahota J, Pellegrini F, Hyde R, Duquette P, Lechner-Scott J, Sajedi SA, Lalive P, Shaygannejad V, Ozakbas S, Eichau S, Alroughani R, Terzi M, Girard M, Kalincik T, Grand'Maison F, Skibina O, Khoury SJ, Yamout B, Sa MJ, Gerlach O, Blanco Y, Karabudak R, Oreja-Guevara C, Altintas A, Hughes S, McCombe P, Ampapa R, de Gans K, McGuigan C, Soysal A, Prevost J, John N, Inshasi J, Stawiarz L, Manouchehrinia A, Forsberg L, Sellebjerg F, Glaser A, Pontieri L, Joensen H, Rasmussen PV, Sejbaek T, Poulsen MB, Christensen JR, Kant M, Stilund M, Mathiesen H, Hillert J; Big MS Data Network: a collaboration of the Czech MS Registry, the Danish MS Registry, Italian MS Registry, Swedish MS Registry, MSBase Study Group, and OFSEP. Spelman T, et al. Front Neurol. 2023 Dec 22;14:1274194. doi: 10.3389/fneur.2023.1274194. eCollection 2023. Front Neurol. 2023. PMID: 38187157 Free PMC article.
Patients not diagnosed with RRMS or RRMS patients not initiating DMT therapy during the RRMS phase were excluded from the analysis. The primary study outcome was treatment switching. ...Consideration of a patient's individual risk and tolerance profile needs to be taken in …
Patients not diagnosed with RRMS or RRMS patients not initiating DMT therapy during the RRMS phase were excluded from the analysis. T …
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.
Reiter A, Schwaab J, DeAngelo DJ, Gotlib J, Deininger MW, Pettit KM, Alvarez-Twose I, Vannucchi AM, Panse J, Platzbecker U, Hermine O, Dybedal I, Lin HM, Rylova SN, Ehlert K, Dimitrijević S, Radia DH. Reiter A, et al. Blood Adv. 2022 Nov 8;6(21):5750-5762. doi: 10.1182/bloodadvances.2022007539. Blood Adv. 2022. PMID: 35640224 Free PMC article. Clinical Trial.
Avapritinib, a potent, highly selective D816V-mutant KIT inhibitor, is approved for treatment of adults with AdvSM by the US Food and Drug Administration, regardless of prior therapy, and the European Medicines Agency for patients with prior systemic therapy, based …
Avapritinib, a potent, highly selective D816V-mutant KIT inhibitor, is approved for treatment of adults with AdvSM by the US Food and Drug A …
Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project.
Gallacher J, de Reydet de Vulpillieres F, Amzal B, Angehrn Z, Bexelius C, Bintener C, Bouvy JC, Campo L, Diaz C, Georges J, Gray A, Hottgenroth A, Jonsson P, Mittelstadt B, Potashman MH, Reed C, Sudlow C, Thompson R, Tockhorn-Heidenreich A, Turner A, van der Lei J, Visser PJ; ROADMAP Consortium. Gallacher J, et al. J Alzheimers Dis. 2019;67(2):495-501. doi: 10.3233/JAD-180370. J Alzheimers Dis. 2019. PMID: 30584137 Free PMC article.
Fabry in the older patient: Clinical consequences and possibilities for treatment.
Lidove O, Barbey F, Niu DM, Brand E, Nicholls K, Bizjajeva S, Hughes DA. Lidove O, et al. Mol Genet Metab. 2016 Aug;118(4):319-25. doi: 10.1016/j.ymgme.2016.05.009. Epub 2016 May 14. Mol Genet Metab. 2016. PMID: 27221354 Free article.
Age groups were defined using age at treatment initiation or at FOS entry for untreated patients: 18-49 (n=1344; 49.5% male; 64.6% received agalsidase alfa enzyme replacement therapy [ERT]); 50-64 (n=537; 35.4% male; 74.3% treated); 65-74 (n=137; 32.1% male; 68.6% treated) …
Age groups were defined using age at treatment initiation or at FOS entry for untreated patients: 18-49 (n=1344; 49.5% male; 64.6% received …
15 results